Cerevance is a drug discovery company advancing treatments for brain diseases. The company’s lead program, Cerevance has 5 compounds under development.. The aim of development for CVN766 is to treat psychiatric disorders including negaive and cognitive symptoms of schizophrenia. Craig Thompson is the current CEO.
×
Cerevance – CVN766
Receive our NewslEtter
Sign up to stay informed about the latest news and opportunities with LRI!
We respect your privacy. You can unsubscribe at any time.
Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.
© 2025 Lifespan Research Institute – ALL RIGHTS RESERVED